
Lp(a) Drug Pelacarsen Fails to Cut Heart Attacks: Full Results
Despite sharply lowering an inherited cholesterol particle, the injectable drug pelacarsen performed no better than placebo at preventing heart events over nearly five years.
By
Lana Pine| Published on November 19, 2026
Fact checked by:
Afton Woodward5 min read
A drug that sharply lowered lipoprotein(a), an inherited cholesterol particle linked to heart disease, did not reduce heart attacks, strokes or cardiovascular deaths, according to full results of the Phase 3 Lp(a)HORIZON trial.
The detailed results were presented Nov. 7 at the American Heart Association’s Scientific Sessions 2026 and published in the New England Journal of Medicine. They expand on topline results announced in September, which The Educated Patient previously covered.
What Is Lipoprotein(a)?
Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle similar to LDL, or “bad” cholesterol. Its level is set largely by genetics and stays stable over a lifetime. High Lp(a) raises the risk of heart attack and stroke, even in people whose LDL cholesterol is well controlled. Diet and exercise do little to change it, and no medication in the United States is approved to lower it specifically.
Pelacarsen, developed by Novartis and Ionis Pharmaceuticals, is an antisense oligonucleotide, a type of drug that blocks the liver from making a key building block of Lp(a). Lp(a)HORIZON was the first completed cardiovascular outcomes trial of a drug designed specifically to lower Lp(a), so its results were closely watched.
Lp(a) Dropped 78%, but Heart Events Did Not
The trial randomly assigned 8,350 adults at 797 sites in 42 countries to monthly injections of pelacarsen 80 milligrams or placebo. Participants were 18 to 80 years old, had a previous heart attack, had ischemic stroke or symptomatic peripheral artery disease, and had an Lp(a) level of at least 70 milligrams per deciliter.
After 12 months, Lp(a) fell 78.4% with pelacarsen compared with 3.2% with placebo.
The main outcome combined cardiovascular death, nonfatal heart attack, nonfatal ischemic stroke and urgent procedures to restore blood flow to the heart. Over a median follow-up of 4.7 years, it occurred in 12.3% of people taking pelacarsen and 12.1% of people taking placebo. There were no differences in any prespecified subgroup, including patients with the highest Lp(a) levels.
“Although these results are disappointing, they provide scientific insights that help inform future research efforts,” said Steven E. Nissen, M.D., senior author and chief academic officer of the Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic.
Side Effects Led Many Patients to Stop Treatment
Pelacarsen caused more bothersome side effects than placebo. Flu-like reactions occurred in 31.9% of people taking pelacarsen compared with 5.8% on placebo, and injection-site reactions in 25.6% compared with 2.9%. Nineteen people taking pelacarsen had confirmed anaphylaxis, a severe allergic reaction, compared with none on placebo.
Side effects led 20.6% of people taking pelacarsen to stop treatment permanently, compared with 7.5% on placebo. Serious adverse events were not more common with the drug (37.3% versus 41.1%).
Why Didn’t Lowering Lp(a) Help?
Researchers offered several possible explanations. Participants’ other risk factors were already well managed. Their median LDL cholesterol was about 65 milligrams per deciliter, and about 78% took high-intensity statins. That may have left little room for an added benefit.
Others asked whether participants’ heart disease was already too advanced to reverse, or whether the Lp(a) that remained still carried risk. The investigators also noted that a few years of Lp(a) lowering may not match the benefit genetic studies link to lifelong lower levels. The large number of people who stopped treatment may have made any benefit harder to detect.
Nissen also stressed that “a single trial does not provide definitive evidence of a lack of benefit” of lowering Lp(a).
Should You Still Get Your Lp(a) Tested?
Yes. The 2026 ACC/AHA multisociety guideline on managing cholesterol recommends Lp(a) testing in all adults. People with elevated Lp(a) should work to manage their other heart risk factors, such as lifestyle habits and LDL cholesterol. Because high Lp(a) runs in families, relatives may also benefit from testing.

